针对儿科性结肠炎的单克隆抗体:临床进展的综述
Debora Curci1, Marianna Lucafò2, Giuliana Decorti3
1Institute for Maternal and Child Health, IRCCS "Burlo Garofolo", Trieste, Italy.
单克隆抗体为儿科性结肠炎 (UC) 提供了有前途的治疗方法,改善了患者的治疗结果和生活质量. 这些先进的疗法为皮质类固醇提供了更安全的替代方案,特别是对于患有严重疾病的儿童.
科学领域:
- 儿科胃肠病学 儿科胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 儿童性结肠炎 (UC) 通常比成年人更严重和更广泛.
- 由于急性恶化导致的住院治疗影响了大约25%的儿科UC患者.
- 通常用于UC的皮质类固醇在儿童中具有显著的副作用.
研究的目的:
- 审查单克隆抗体用于治疗儿科UC的使用.
- 讨论针对瘤亡因子 (TNF) α和其他炎症途径的生物药物.
- 为突出儿童UC个性化治疗的进步.
主要方法:
- 使用关键词进行文献搜索:"儿科"",性结肠炎"",单克隆抗体"",infliximab"",adalimumab"",golimumab"",vedolizumab"",ustekinumab"",risankizumab"等.
- 审查当前的治疗策略和临床结果.
- 分析安全概况和个性化治疗.
主要成果:
- 在儿科UC中使用单克隆抗体显著增加.
- 这些疗法用于对常规治疗不耐药的患者,并且越来越多地作为初始治疗.
- 治疗药物监测和多种生物标使得个性化治疗成为可能.
结论:
- 单克隆抗体已经改变了儿科UC的治疗格局.
- 用生物药物进行个性化治疗可以提高反应率和生活质量.
- 这些治疗方法为儿童性结肠炎的管理提供了有利的安全性.
更多相关视频
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
07:05Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation
Published on: December 15, 2017
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
